WHO Drug Information Vol. 14, No. 1, 2000
(2000; 81 pages) View the PDF document
Table of Contents
Open this folder and view contentsGeneral Policy Issues
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsCurrent Topics
Open this folder and view contentsVaccines and Biomedicines
Open this folder and view contentsGeneral Information
Close this folderRegulatory and Safety Matters
View the documentTroglitazone withdrawn
View the documentCisapride and cardiac effects
View the documentCisapride: changes to labelling
View the documentCisapride: updated warning issued
View the documentSt John's wort: recommendations for use
View the documentNorthern hemisphere influenza vaccine
View the documentNicotine replacement therapy
View the documentAnorectic agents: suspension of marketing authorization
View the documentInsulin cartridges: leakage risk
View the documentZimox®: trade name duplication and risk of errors
View the documentBenzbromarone and hepatitis
View the documentNevirapine: severe cutaneous reactions
View the documentFDA cannot regulate tobacco industry
View the documentNew Internet website: information for consumers
View the documentCyber warnings for drug sales via the Internet
View the documentTriax®: a harmful product sold on the Internet
View the documentIllegal products on the market
View the documentEpoetin alfa: inappropriate practices compromise product sterility
View the documentPropylene glycol and amprenavir
View the documentTrastuzumab: pulmonary reactions
Open this folder and view contentsATC/DDD Classification
Open this folder and view contentsRecent Publications and Documents
Open this folder and view contentsInternational Nonproprietary Names for Pharmaceutical Substances (INN)
View the documentSelected WHO Publications of Related Interest
 

Zimox®: trade name duplication and risk of errors

Islamic Republic of Iran - The Tehran Drug and Poison Information Centre has informed the World Health Organization that a combination product containing the anti-Parkinson drugs carbidopa and levodopa is being imported into Iran from Greece with the trade name Zimox®. Zimox® is also the name of a product well known to contain the anti biotic amoxicillin and is cited in reference books such as Martindale and Index Nominum.

The Centre is concerned about the potential for error that could result from this duplication of trade names. Information has been forwarded to the national drug authorities in order to avoid preventable mistakes in the dispensing of Zimox®, and an announcement has also been circulated to health professionals.

The Centre urges pharmaceutical companies to establish beforehand whether the names chosen for their products have not already been used.

Reference: Communication from the Tehran Drug and Poison Information Centre, 24 November 1999.

to previous section to next section
 

Last updated: May 3, 2013